Described herein are engineered metabolic pathways in recombinant microorganism host cells which result in the production of 2-phenylethanol or 2-phenylacetic acid. Also described herein are methods of using the recombinant microorganisms for the production of 2-phenylethanol or 2-phenylacetic acid.

The invention concerns a genetically modified microorganism expressing a functional type I or II RuBisCO enzyme and a functional phosphoribulokinase (PRK), and in which the glycolysis pathway is at least partially inhibited, said microorganism being genetically modified so as to produce an exogenous molecule and/or to overproduce an endogenous molecule. According to the invention, the oxidative branch of the pentose phosphate pathway may also be at least partially inhibited. The invention also concerns the use of such a genetically modified microorganism for the production or overproduction of a molecule of interest and processes for the synthesis or bioconversion of molecules of interest.

The present invention relates to a genetically engineered microorganism expressing (i) formate tetrahydrofolate (THF) ligase, methenyi-THF cyclohydrolase and methylene-THF dehydrogenase, (ii) the enzymes of the glycine cleavage system (GCS), (iii) serine deaminase and serine hydroxymethyltransferase (SHMT), (iv) an enzyme increasing the availability of NADPH, and (v) optionally formate dehydrogenase (FDH), and wherein the genetically engineered microorganism has been genetically engineered to express at least one of the enzymes of (i) to (v), wheren said enzyme is not expressed by the corresponding microorganism that has been used to prepare the genetically engineered microorganism, and wherein the enzymes of (i) to (v) are genomically expressed.

The present disclosure relates to a microorganism of the genus Corynebacterium having an increased L-amino acid producing ability, containing NADP-dependent glyceraldehyde-3-phosphate dehydrogenase derived from the genus Lactobacillus. According to the present disclosure, the NADP-dependent glyceraldehyde-3-phosphate dehydrogenase derived from Lactobacillus delbrueckii subsp. bulgaricus is introduced to increase the reducing power through the activity of NADP-dependent glyceraldehyde-3-phosphate dehydrogenase, thereby increasing the L-amino acid producing ability of the strains belonging to the genus Corynebacterium.

Metabolites produced by a microorganism using oxaloacetate, pyruvate and/or acetyl-CoA as substrate or co-substrate upstream in the biosynthesis pathway, and more particularly using oxaloacetate. There is indeed a need in the art for transformed, in particular recombinant, microorganisms having at least an increased ability to produce oxaloacetate, pyruvate and/or acetyl-CoA, and in particular oxaloacetate, thus allowing an increased capacity to produce metabolites produced using oxaloacetate, pyruvate and/or acetyl-CoA as substrate or co-substrate upstream in the biosynthesis pathway, and in particular amino acids and their derivatives thereof, fatty acids, derivatives from the mevalonate pathway (in particular farnesyl, squalene, lanosterol, cholesterol and derivatives, and dolichols), flavonoides and/or polyketides. The solution proposed is the use of a genetically modified yeast comprising many modifications as described in the present text.

The invention provides genetically engineered microorganisms and methods for the biological production of ethylene glycol and precursors of ethylene glycol. In particular, the microorganism of the invention produces ethylene glycol or a precursor of ethylene glycol through one or more of 5,10-methylenetetrahydrofolate, oxaloacetate, citrate, malate, and glycine. The invention further provides compositions comprising ethylene glycol or polymers of ethylene glycol such as polyethylene terephthalate.

Disclosed herein are compositions and methods for detecting antibodies directed to epitopes of the metabolic enzymes, fructose-1,6-bisphosphate aldolase (A), α-enolase (E), and glyceraldehyde-3-phosphate dehydrogenase (G), that are shared between T. vaginalis and human AEG proteins.

The invention provides non-naturally occurring microbial organisms containing a fatty alcohol, fatty aldehyde or fatty acid pathway, wherein the microbial organisms selectively produce a fatty alcohol, fatty aldehyde or fatty acid of a specified length. Also provided are non-naturally occurring microbial organisms having a fatty alcohol, fatty aldehyde or fatty acid pathway, wherein the microbial organisms further include an acetyl-CoA pathway. In some aspects, the microbial organisms of the invention have select gene disruptions or enzyme attenuations that increase production of fatty alcohols, fatty aldehydes or fatty acids. The invention additionally provides methods of using the above microbial organisms to produce a fatty alcohol, a fatty aldehyde or a fatty acid.

Provided herein are compositions and methods for treating succinic semialdehyde dehydrogenase deficiency (SSADHD). Compositions may include a gene encoding a functional succinic semialdehyde dehydrogenase (SSADH) enzyme, such as ALDH5A1, operably linked to a targeting vector. The functional SSADII enzyme is envisioned to lower the levels of circulating gamma-hydroxybutyric acid (GHB) and γ-aminobutyric acid (GABA). In some embodiments, combination therapies are envisioned, comprising administering to the subject therapeutically effective amounts of a combination of a composition comprising a gene encoding a functional SSADII enzyme operably linked to a targeting vector; one or more mTOR inhibitors; and a GABA-T inhibitor. Suitable mTOR inhibitors include rapamycin, while suitable GABA-T inhibitors include vigabatrin.

The present invention discloses an engineering yeast strain for producing nervonic acids. The yeast strain over-expresses the genes related to enzymes required in a synthetic process of long-chain unsaturated fatty acids, such as fatty acid elongase, desaturase, diacylglycerol acyltransferase and the like, and optionally, further adjusts and controls the synthesis and decomposition route of triglyceride, the synthesis and decomposition route of sphingomyelin, and the synthesis and decomposition route and the oxidation-reduction balanced route of lipid subcell levels. The recombinant yeast strain can produce microorganism oil; and the content of the prepared nervonic acids accounts for 39.6% of the total fatty acids.